AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32559027
Drug: Dextroamphetamine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine administration
Trial: 34890069
Drug: MSC‐NTF treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC‐NTF treatment
Trial: 34011040
Drug: Bi Qi
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi Qi Capsules (BQC) in combination with Methotrexate
Trial: 33883477
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity (PA) therapy based on intelligent wearable devices for 8 weeks
Trial: 33883477
Drug: Internet-based modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based modified behavioral activation (BA) therapy for 8 weeks
Trial: 38951007
Drug: Standard Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Oxygen Therapy
Trial: 35586186
Drug: Peficitinib 50
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Peficitinib 50 mg single dose
Trial: 35586186
Drug: Peficitinib 100
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Peficitinib 100 mg single dose
Trial: 35586186
Drug: Peficitinib 150
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Peficitinib 150 mg single dose
Trial: 35586186
Drug: Peficitinib multiple
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Peficitinib multiple doses (50, 100, 150 mg)
Trial: 35586186
Drug: Peficitinib multiple
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Peficitinib multiple doses (higher dose groups)
Trial: 35586186
Drug: Peficitinib multiple
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Peficitinib multiple doses (lower dose groups)
Trial: 34968124
Drug: Suicide prevention-focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suicide prevention-focused group therapy
Trial: 34436928
Drug: Veliparib 120
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib 120 mg twice daily with carboplatin and paclitaxel
Trial: 34436928
Drug: Veliparib with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib with chemotherapy
Trial: 34436928
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with chemotherapy
Trial: 36029162
Drug: Prognostic-efficacy-combination design
RxNorm normalized name: Designer Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prognostic-efficacy-combination design
Trial: 33616557
Drug: ID group
RxNorm normalized name: MenQuadfi, polysaccharide tetanus toxoid group ACYW intramuscular solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ID group (n = 20) with abutment preparations for inlay retainers (proximal box and occlusal extension)
Trial: 33616557
Drug: PB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PB group (n = 10) with only proximal box preparations
Trial: 34957988
Drug: Standardized treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatment
Trial: 33767162
Drug: Low-dose tamoxifen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tamoxifen (5 mg/day)
Trial: 32131824
Drug: Personal characteristics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal characteristics of IFs (e.g., flexible, assertive)
Trial: 34289884
Drug: Twice-weekly KBA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly KBA training (n = 40)
Trial: 34289884
Drug: Thrice-weekly KBA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly KBA training (n = 40)
Trial: 32402555
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab 0.5 mg monthly
Trial: 32402555
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab 0.5 mg pro re nata (PRN) after 3 loading doses
Trial: 32402555
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab 2.0 mg monthly
Trial: 32402555
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab 2.0 mg PRN
Trial: 34162645
Drug: 12-week open-label
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week open-label placebo treatment
Trial: 32213291
Drug: Quetiapine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 12.5 mg every 12 hours
Trial: 34166959
Drug: Pharmacist-led educational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led educational intervention on inhalation technique education via demonstration and repetition
Trial: 33634858
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (NAT) with imatinib, median duration 6.3 months
Trial: 38484209
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (NAT)
Trial: 33634858
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (NAT) vs Upfront resection (UR)
Trial: 36293748
Drug: ANZANSI intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ANZANSI intervention (combination of family economic empowerment and multiple family group family strengthening)
Trial: 34622750
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement of 4% ARA
Trial: 34622750
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement of ARA (various levels)
Trial: 33453192
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy combined with oral medication and exercise
Trial: 33453192
Drug: Sham extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham extracorporeal shock wave therapy combined with oral medication and exercise
Trial: 35351353
Drug: Online self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online self-help using cognitive-behavioral therapy and positive psychology principles (n = 301)
Trial: 34196269
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy plus standardised medical care
Trial: 32824061
Drug: Mindfulness treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness treatment (flow meditation)
Trial: 33615833
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid infusion
Trial: 32779416
Drug: Antibiotics +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics + bee products
Trial: 34479631
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of treatment
Trial: 33316557
Drug: Carboplatin-based chemotherapy
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin-based chemotherapy
Trial: 32538865
Drug: Weekly ParkinSong
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly ParkinSong
Trial: 32538865
Drug: Monthly ParkinSong
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly ParkinSong
Trial: 32538865
Drug: Monthly control
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly control
Trial: 32538865
Drug: Weekly control
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly control
Trial: 34453873
Drug: 10% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% hydrogen peroxide (HP) gel with prefilled trays (PT) for 30 minutes
Trial: 34453873
Drug: 10% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% hydrogen peroxide (HP) gel with customized trays (CT) for 30 minutes
Trial: 34453873
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide (CP) gel with customized trays (CT) for 2 hours
Trial: 34453873
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide (CP) gel with customized trays (CT) for 8 hours
Trial: 35866767
Drug: PCIA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCIA with low-dose naloxone admixture at 0.2 μg·kg‐1·h‐1 (Group B)
Trial: 35866767
Drug: PCIA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCIA with naloxone admixture at 0.4 μg·kg‐1·h‐1 (Group C)
Trial: 35866767
Drug: PCIA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCIA with naloxone admixture at 0.6 μg·kg‐1·h‐1 (Group D)
Trial: 34407811
Drug: INT-DPM (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INT-DPM (with oral hypoglycaemic medication)
Trial: 35195738
Drug: Single carbon
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single carbon dioxide (CO2) laser maintenance treatment
Trial: 35195738
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment control group
Trial: 36495185
Drug: N-acetylcysteine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine inhalation spray (one puff per 12 hours for 7 days)
Trial: 33588060
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (PDT + isotretinoin 10 mg twice a day for 3 months)
Trial: 33882052
Drug: Daily cigarette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily cigarette smoking
Trial: 32502705
Drug: Transversus abdominis
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transversus abdominis plane block with dexmedetomidine (1 μg/kg)
Trial: 32502705
Drug: Morphine intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine intravenous patient‐controlled analgesia (Control group)
Trial: 33843133
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by pelvic re-irradiation
Trial: 33183258
Drug: Placebo (physiological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (physiological saline solution)
Trial: 33259482
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 supplementation (2 μg daily for 12 months)
Trial: 34865016
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg/day for 12 weeks
Trial: 33285652
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy (RT) for 30 minutes twice a day for 2 weeks
Trial: 33285652
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation (CR) for 30 minutes twice a day for 2 weeks
Trial: 35385097
Drug: 8 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 sessions of cognitive behavioral therapy
Trial: 34323164
Drug: Selinexor 60
RxNorm normalized name: selinexor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 60 mg twice weekly
Trial: 34323164
Drug: Physician’s choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician’s choice (PC) treatment
Trial: 32598447
Drug: Prophylactic fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic fat injections (3 injections according to Coleman's technique) after radiotherapy and before expander removal with definitive implant insertion.
Trial: 32222782
Drug: Metaphor-based visual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaphor-based visual representations of pharmaceutical pollution risks
Trial: 32222782
Drug: Non-metaphor visual
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-metaphor visual representations of pharmaceutical pollution risks
Trial: 35106315
Drug: MHAA4549A (3600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MHAA4549A (3600 mg or 8400 mg)
Trial: 35246827
Drug: fosnetupitant 235
RxNorm normalized name: fosnetupitant 235 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosnetupitant 235 mg
Trial: 34076981
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate combined with rituximab (HD-MTX + R)
Trial: 34076981
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate combined with whole brain radiotherapy (WBRT)
Trial: 35109906
Drug: Topical hydrogen
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hydrogen peroxide
Trial: 33271112
Drug: Perioperative endocrine
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative endocrine therapy
Trial: 99050129
Drug: Cocaine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (80 mg/70 kg, p.o.)
Trial: 99050129
Drug: d-amphetamine (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (5, 10, 20 mg/70 kg, p.o.)
Trial: 99050129
Drug: Caffeine (150,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (150, 300, 600 mg/70 kg, p.o.)
Trial: 32827162
Drug: Eflapegrastim (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflapegrastim (fixed dose of 13.2 mg, 3.6 mg G-CSF)
Trial: 32687266
Drug: Pegfilgrastim (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim (6 mg G-CSF)
Trial: 33946029
Drug: Curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplementation (80 mg daily for 8 weeks)
Trial: 34247409
Drug: Flexible dosing
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible dosing regimen (higher dose)
Trial: 34247409
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (control)
Trial: 32522771
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by surgery (Arm A): three cycles of paclitaxel and cisplatin followed by type C radical hysterectomy and pelvic ± paraaortic lymphadenectomy.
Trial: 32522771
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (Arm B): definitive concurrent chemoradiotherapy including external beam pelvic radiotherapy combined with concurrent weekly cisplatin followed by brachytherapy.
Trial: 35546450
Drug: Once-weekly semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly semaglutide (n=874)
Trial: 35546450
Drug: Thrice-daily insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thrice-daily insulin aspart (IAsp) (n=874)
Trial: 36542260
Drug: Once-weekly semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly semaglutide
Trial: 35546450
Drug: Thrice-daily insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thrice-daily insulin aspart (IAsp)
Trial: 33044411
Drug: Specific intervention
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific intervention (plasma transfusion, low‐dose unfractionated heparin, and tranexamic acid)
Trial: 33896590
Drug: Induced normothermia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induced normothermia (maintaining core temperature at 37°C using external cooling, cold i.v. fluids, and medications like buspirone, clonidine, and magnesium sulphate)
Trial: 36178169
Drug: High-dose green
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose green tea extract (843 mg/day EGCG)
Trial: 34183565
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol 1 mg tablets
Trial: 34183565
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol plus micronized progesterone (MP)
Trial: 35567872
Drug: N. sativa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N. sativa oil 1000 mg/day for 8 weeks
Trial: 32121339
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g dark chocolate bar
Trial: 32121339
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g white chocolate bar
Trial: 32465723
Drug: Post-implant survival
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-implant survival
Trial: 33507691
Drug: Curcumin +
RxNorm normalized name: Nature's Truth Turmeric Curcumin + Ginger Gummies (Peach)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin + radiation therapy
Trial: 33507691
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + radiation therapy
Trial: 34340708
Drug: 3200 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3200 IU/day oral vitamin D3 for 12 weeks
Trial: 34162485
Drug: Low-dose direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose direct acting oral anticoagulants (LDDOAC)
Trial: 35064063
Drug: Prescription drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription drug misuse campaign (control)
Trial: 32471854
Drug: Fast-acting treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-acting treatment (BeSt and IMPROVED)
Trial: 32471854
Drug: Slow-acting treatment
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-acting treatment (BeSt)
Trial: 32471854
Drug: Slow-acting monotherapy
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-acting monotherapy
Trial: 32471854
Drug: Fast-acting treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-acting treatment (BeSt)
Trial: 32471854
Drug: Fast-acting treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-acting treatment (IMPROVED)
Trial: 34765938
Drug: Early access
RxNorm normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Early access to antiretroviral therapy (ART)
Trial: 34765938
Drug: Late access
RxNorm normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Late access to antiretroviral therapy (ART)
Trial: 36075590
Drug: Electroacupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture combined with intradermal needling
Trial: 32897010
Drug: Antibacterial therapy
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial therapy (ABT) + recombinant interferon alpha‐2b with antioxidant complex (vitamins E and C)
Trial: 32897010
Drug: Antibacterial therapy
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial therapy (ABT)
Trial: 35270910
Drug: Active coil
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active coil stimulation for tests and placebo coil stimulation for treatment (APA) (n = 15)
Trial: 32299820
Drug: Low-dose carfilzomib
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose carfilzomib (27 mg/m2) with dexamethasone
Trial: 32299820
Drug: High-dose carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose carfilzomib (56 mg/m2) with dexamethasone
Trial: 32299820
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to high-dose carfilzomib (56 mg/m2) after progression on low-dose
Trial: 32299820
Drug: High-dose carfilzomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose carfilzomib (56 mg/m2)